

## **CROTALUS DURISSUS TERRIFICUS VENOM: CROTOXIN AND INTER-CRO**

*Carlos Julio Laure*, Department of Biochemistry, Faculty of Medicine of Ribeirão Preto, University of São Paulo.

Crotoxin from *Crotalus durissus terrificus* represents almost 50% of the dry weight of the venom and is the main toxic component of the latter.<sup>6</sup> Crotoxin was separated into two fractions by two different methods, using carboxymethyl-cellulose and DEAE-cellulose chromatography:<sup>15,9</sup> an acid, nontoxic fraction denoted Crotopotin, and a basic, low toxicity fraction with enzymatic activity denoted *Phospholipase A<sub>2</sub>*. Crotopotin (acid) potentiates the toxicity of phospholipase A (basic) *in vivo* but inhibits its hemolytic activity *in vitro*.

Both laboratories showed that Crotoxin is a complex formed by the strong association of crotopotin with phospholipase A<sub>2</sub>. The recombination of these fractions restores the toxicity of crotoxin. Phospholipase A<sub>2</sub> has a molecular weight of 15,000 daltons, with a P.I. of 8.6.<sup>15,10</sup> It consists of a single polypeptide chain of 133 residues.<sup>8</sup> The acid component crotopotin has a P.I. of 3.4 and a molecular weight of 9,000 daltons according to Horst<sup>10</sup>, and a P.I. of 3.7 according to Breithaupt,<sup>5</sup> who, however, determined the same molecular weight. Breithaupt<sup>5</sup> reduced crotopotin with  $\beta$ -mercaptoethanol followed by carboxamide methylation and separated three peptide chains linked by disulfide bridges:

Chain A with 40 amino acid residues, MW 4,300

Chain B with 34 amino acid residues, MW 3,700

Chain C with 14 amino acid residues, MW 1,600

The N-terminal of the peptide chains only supplies serine for chain A, indicating that the N-terminals of chains B and C are blocked.<sup>5</sup> Crotoxin at high doses acts on the post-synaptic membranes, stabilizing the acetylcholine receptors.<sup>3,17</sup> Crotopotin only potentiates the toxicity of crotalic phospholipase A, a fact that could be interpreted as a pharmacokinetic phenomenon. This acid fraction can protect phospholipase A against inactivation by binding to low affinity sites, thus preserving it for high-affinity receptors.

There is no evidence of *in vivo* formation of the crotoxin complex. Jeng<sup>11</sup> and Bon<sup>2</sup> proposed a model which they called "chaperon" effect for crotopotin,



## REFERENCES

1. AIRD, S.D.; KAISER, I.I.; LEWIS, R.V.; KRUGGEL, G.W. Rattlesnake presynaptic neurotoxins; primary structure and evolutionary origin of the acidic subunit. *Biochemistry*, 24:7054-7058, 1985.
2. BON, C. & JENG, T.W. In: CECCARELLI & CLEMENT, ed. *Advances in cytopharmacology*. New York, Raven Press, 1979.
3. BON, C.; CHANGEUX, J.P.; JENG, T.W.; FRAENKEL-CONRAT, H. *Eur. J. Biochem.*, 99:471-481, 1979.
4. BON, C.; CHOUMET, V.; FAURE, G.; YIANG, M.S.; LEMBEZAT, M.P.; RADVANYI, F.; SALIOU, B. Crotoxin, half-century of investigations on a phospholipase neurotoxin. In: SIMPÓSIO ANUAL DA ACIESP SOBRE TOXINAS PROTÉICAS, 12. *Anais*. Campinas, ACIESP, 1988. p. 9-18.
5. BREITHAUPT, H.; RÜBSAMEN, K.; HABERMAN, E. *Eur. J. Biochem.*, 49:333, 1974.
6. FAURE, G. & BON, C. Several isoforms of crotoxin are present in individual venoms from the South American rattlesnake *Crotalus durissus terrificus*. *Toxicon*, 25:229-234, 1987.
7. FAURE, G. & BON, C. Crotoxin, a phospholipase A<sub>2</sub> neurotoxin from the South American rattlesnake *Crotalus durissus terrificus*; purification of several isoforms and comparison of their molecular structure and of their biological activities. *Biochemistry*, 27:730-738, 1988.
8. FRAENKEL-CONRAT, H.; JENG, T.W.; HSTANG, M. Biological activities and amino acid sequence of crotoxin B. In: FAKER, D & WADSTRÖM, T. ed. *Natural toxins*. Intern-Symp. Animal, Plant and Microbial Toxins, 6. *Proc. Oxford, N.Y.*, Pergamon Press, 1980.
9. HENDON, R.A. & FRAENKEL-CONRAT, H. *Proc. Natl. Acad. Sci. USA*, 68:1560, 1971.
10. HORST, J.; HENDON, R.A.; FRAENKEL-CONRAT, H. *Biochem. Biophys. Res. Comm.*, 46:1042, 1972.
11. JENG, T.W.; HENDON, R.A.; FRAENKEL-CONRAT, H.L. *Proc. Natl. Acad. Sci. USA*, 75:600, 1978.
12. KAISER, I.I.; AIRD, S.D.; KRUGGEL, W.; LEWIS, R.V. In: WORLD CONGRESS ON ANIMAL, PLANT AND MICROBIAL TOXINS, 8. United Kingdom, Newcastle upon Tyne, 1985. p. 579.
13. LAURE, C.J. (1980). Master's Thesis, Gabilan N. (1984). Estrutura primária da cadeia C da crotapotina, FMRP-USP; Conti, M.A.B. (1986). Estrutura primária da cadeia B da crotapotina. Doctoral Thesis, FMRP-USP and Estrutura primária da cadeia A, Saito, Y. e Laure, C.J. FMRP-USP (1986).
14. LAURE, C.J. Oral communication. Simpósio Anual da ACIESP, 12. *Anais*. 1988.
15. RÜBSAMEN, K.; BREITHAUPT, H.; HABERMAN, E. *Naunyn-Schmie. Arch. Exp. Path. Pharmacol.*, 279: 274, 1971.
16. SLOTTA, K. & FRANKEL-CONRAT, H. *Ber. Dtsch. Chem. Ges.*, 71:1076-1081, 1938.
17. VITAL BRAZIL, O. Pharmacology of crystalline crotoxin. II. Neuromuscular blocking action. *Mem. Inst. Butantan*, 33:981-992, 1966.

